Rein Therapeutics (015A) AI Stock Analysis

Rein Therapeutics

(Berlin:015A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical validation and Phase 2 progressLTI-03 has advanced beyond early safety testing with a met Phase 1b primary endpoint and tolerability at both tested doses. Enrollment in Phase 2 gives the lead program a clearer development path and creates an opportunity to validate efficacy in IPF.

Negative Factors

Pre-revenue business with substantial lossesRein has no commercial revenue to offset research and operating costs, while its nearly $49.8M TTM net loss shows that the business remains far from self-sustaining. Future financial strength therefore depends heavily on successful development and eventual commercialization.

Rein Therapeutics (015A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 54.81M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Rein Therapeutics Business Overview & Revenue Model

Company Description

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a d...

Rein Therapeutics Risk Analysis

Rein Therapeutics disclosed 68 risk factors in its most recent earnings report. Rein Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.32 PART II—OTHER INFORMATIONItem 1A. Risk Factors.For a discussion of our risk factors, see “Part I, Item 1A-Risk Factors” in our Annual Report for the year ended December 31, 2025.You should carefully consider the risks included in our Annual Report, together with all of the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. The occurrence of any single risk or any combination of risks could materially and adversely affect our business, financial condition, results of operations, cash flows and the trading price of our common stock.Q2, 2026

Rein Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:015A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCY	45Neutral	$54.24M	-1.63	1020.21%	―	―	2.05%
XLO	44Neutral	$52.84M	-5.36	-50.77%	―	327.25%	85.65%
CRDF	43Neutral	$69.21M	-1.41	-103.08%	―	-6.96%	32.77%
ELTX	42Neutral	$45.51M	-0.75	-1266.43%	―	―	49.43%

* Healthcare Sector Average

Performance Comparison

DE:015A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:015A	Rein Therapeutics, Inc	3.14	0.00	0.00%
ONCY	Oncolytics Biotech	0.40	-0.56	-58.51%
CRDF	Cardiff Oncology, Inc.	0.84	-1.38	-61.98%
XBIT	XBiotech Inc.	1.92	-0.24	-11.11%
ELTX	Elicio Therapeutics, Inc	1.59	-7.56	-82.62%
XLO	Xilio Therapeutics Inc	7.99	-3.23	-28.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Rein Therapeutics AI Stock Analysis